Edition:
United Kingdom

Clementia Pharmaceuticals Inc (CMTA.OQ)

CMTA.OQ on NASDAQ Stock Exchange Global Select Market

16.09USD
12 Dec 2017
Change (% chg)

$0.08 (+0.50%)
Prev Close
$16.01
Open
$15.70
Day's High
$16.39
Day's Low
$15.70
Volume
11,499
Avg. Vol
18,168
52-wk High
$18.95
52-wk Low
$15.05

Chart for

About

Clementia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and... (more)

Overall

Beta: --
Market Cap(Mil.): $474.83
Shares Outstanding(Mil.): 29.68
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Clementia Initiates Pivotal Phase 3 MOVE Trial For Palovarotene

* CLEMENTIA INITIATES PIVOTAL PHASE 3 MOVE TRIAL FOR PALOVAROTENE IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA

12 Dec 2017

BRIEF-Clementia Pharmaceuticals qtrly loss per share ‍$1.83​

* Clementia Pharmaceuticals Inc - qtrly loss per share ‍$1.83​

13 Nov 2017

BRIEF-Clementia announces closing of over-allotment option in its IPO

* Clementia announces closing of over-allotment option in its initial public offering Source text for Eikon: Further company coverage:

21 Aug 2017

BRIEF-Clementia announces pricing of initial public offering

* Says initial public offering of 8.00 million common shares priced at $15.00per share Source text for Eikon: Further company coverage:

02 Aug 2017

BRIEF-Clementia Pharmaceuticals sees IPO of 7.2 mln shares priced between $13-$15/shr

* Clementia Pharmaceuticals Inc sees IPO of 7.2 million shares of its common shares priced between $13-$15 per share - SEC filing

21 Jul 2017

Earnings vs. Estimates